PMID- 24118906
OWN - NLM
STAT- MEDLINE
DCOM- 20141209
LR  - 20181202
IS  - 1752-699X (Electronic)
IS  - 1752-6981 (Linking)
VI  - 8
IP  - 2
DP  - 2014 Apr
TI  - The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated 
      advanced non-small cell lung cancer patients in China.
PG  - 206-12
LID - 10.1111/crj.12059 [doi]
AB  - BACKGROUND: Sunitinib is an oral multitargeted tyrosine kinase inhibitor (TKI) 
      exhibiting antiagiogenic and antitumor effects. OBJECTIVE: To evaluate the 
      efficacy and potential toxicity of sunitinib therapy in advanced non-small cell 
      lung cancer (NSCLC) patients in China. METHODS: From January 2009 to August 2011, 
      30 patients with stage IV NSCLC, who were pretreated with the epidermal growth 
      factor receptor (EGFR)-TKIs and then received sunitinib, were retrospectively 
      reviewed. Univariate and multivariate Cox proportional hazard regression analysis 
      was performed to determine the potential prognostic risk factors influencing 
      NSCLC survival. RESULTS: The median progression-free survival (PFS) and median 
      overall survival (OS) of all 30 treated patients was 1.25 months [95% confidence 
      interval (CI): 0.90-1.9 months] and 3.40 months (95% CI: 3.00-6.80 months), 
      respectively. Cox regression analysis suggested that Eastern Cooperative Oncology 
      Group (ECOG) performance status (PS) is predictive of both PFS (P=0.001) and OS 
      (P<0.001). Common adverse events (AEs) included hand-foot syndrome (53.3%), 
      mucositis (40.0%), rash (36.7%) and diarrhea (33.3%). CONCLUSION: No sign of 
      overall clinical benefits of sunitinib was detected in patients with pretreated 
      EGFR-TKIs. Most patients suffered AEs from mild to moderate severity. ECOG PS is 
      highly associated with PFS and OS rate. Further studies in NSCLC are required to 
      determine whether sunitinib is beneficial nor not.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - Liu, You-ru
AU  - Liu YR
AD  - Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, 
      Shanghai, China.
FAU - Zhu, Wei
AU  - Zhu W
FAU - Zhang, Jian-liang
AU  - Zhang JL
FAU - Huang, Jia-qi
AU  - Huang JQ
FAU - Zhao, Yi-zhuo
AU  - Zhao YZ
FAU - Zhang, Wei
AU  - Zhang W
FAU - Han, Bao-hui
AU  - Han BH
FAU - Yao, Yi-hong
AU  - Yao YH
FAU - Jiang, Li-yan
AU  - Jiang LY
FAU - Li, Shan-Qun
AU  - Li SQ
LA  - eng
PT  - Journal Article
DEP - 20131211
PL  - England
TA  - Clin Respir J
JT  - The clinical respiratory journal
JID - 101315570
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/mortality
MH  - China/epidemiology
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Drug
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Indoles/*administration & dosage
MH  - Lung Neoplasms/*drug therapy/metabolism/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
MH  - Pyrroles/*administration & dosage
MH  - Receptor, ErbB-2/*antagonists & inhibitors
MH  - Retrospective Studies
MH  - Sunitinib
MH  - Survival Rate/trends
MH  - Treatment Outcome
OTO - NOTNLM
OT  - EGFR-TKI
OT  - NSCLC therapy
OT  - erlotinib
OT  - gefitinib
OT  - lung neoplasms
OT  - sunitinib
EDAT- 2013/10/15 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/10/15 06:00
PHST- 2013/04/15 00:00 [received]
PHST- 2013/09/05 00:00 [revised]
PHST- 2013/09/22 00:00 [accepted]
PHST- 2013/10/15 06:00 [entrez]
PHST- 2013/10/15 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1111/crj.12059 [doi]
PST - ppublish
SO  - Clin Respir J. 2014 Apr;8(2):206-12. doi: 10.1111/crj.12059. Epub 2013 Dec 11.